Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Daito Pharmaceutical Co.,Ltd.. A complete text table follows the diagram.
Finished formulations grow on generic demand while APIs reset and inventory discipline restores profitability.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Active pharmaceutical ingredients | 1 | 11.3B | 45.0% of reported total |
| Finished formulations | 1 | 13.7B | 54.6% of reported total |
| Health foods & other | 1 | 100M | 0.4% of reported total |
| Other & rounding | 1 | 1M | 0.0% of reported total |
| Revenue | 2 | 25.1B | JPY25.141B interim sales |
| Product categories | 3 | 25.1B | API, finished formulations and health foods |
| Product-category table rounding | 3 | 1M | Management sales categories rounded to the nearest JPY1M |
| From | To | Value |
|---|---|---|
| Active pharmaceutical ingredients | Revenue | 11.3B |
| Finished formulations | Revenue | 13.7B |
| Health foods & other | Revenue | 100M |
| Other & rounding | Revenue | 1M |
| Revenue | Product categories | 25.1B |
| Revenue | Product-category table rounding | 1M |